Introduction
HLA-G is one of the 'non-classical' HLA-class Ib molecules, and its main physiological role is the abrogation of maternal NK cell activity against semi-allogeneic fetal tissue, leading to the establishment of immune tolerance at the maternal-fetal interface (1) . During the last few years, the role of HLA-G as immunoregulatory molecule in several pathological conditions (i.e. tumors, viral infections and autoimmune disorders) has been extensively described (2, 3) .
HLA-G has seven different isoforms that are generated from a single primary transcript through alternative splicing. The expression of membrane-bound molecules (HLA-G1, -G2, -G3 and -G4) and the release of soluble molecules (HLA-G5, -G6, -G7 and soluble HLA-G1, which is generated by shedding from the membrane-bound molecule) have been detected in different cell populations (4) . Moreover, soluble (s)HLA-G molecules are present in body fluids (i.e. serum, plasma, cerebrospinal fluid, synovial fluid), and their concentration is often altered in pathological conditions (2, 3) .
HLA-G molecules can interact with four different receptors that are expressed on different cell populations: (i) human inhibitory receptors immunoglobulin-like transcript (ILT) 2/CD85j on NK cells, B cells, T cells, monocytes and macrophages, (ii) ILT4/CD85d on monocytes and macrophages, (iii) CD160 on NK cells, T cells and endothelial cells (5) and (iv) killer cell immunoglobulin-like receptor 2DL4 on NK cells and CD8 + T cells (3, 6) . The interaction of HLA-G with different receptors leads to different effects on different target cells, that is induction of apoptosis (7), inhibition of cell proliferation (8) , cytotoxicity (9), differentiation (10), chemotaxis (11, 12) and modulation of cytokine release (12, 13) . sHLA-G has an important role in the control of CD4 + T-cell functions by inhibiting cell proliferation (8), cell cycle progression (14) and activation (15) . Moreover, we have recently demonstrated that sHLA-G down-modulates the expression of different chemokine receptors on different T-cell subsets, including CD4 + T cells, leading to the inhibition of chemotaxis of these cells toward their specific ligands (11) .
So far, no information is available on possible modulation of micro (mi)RNA expression induced by sHLA-G. miRNAs have been described in the last few years as key modulators of gene expression (16) . Moreover, their relevance in the control of the function of different cells of the immune system is constantly increasing (17) . In particular, miRNAs have a fundamental role in the control of CD4 + T cell functions, targeting different transcriptional factors (18, 19) that in turn may regulate the expression of several genes, including cytokines (20, 21) , membrane-bound (22) and signaling molecules (23) or enzymes (24) .
In this paper, we analyzed for the first time sHLA-G-mediated modulation of the expression of different miRNAs that have been previously associated with inflammation, leukemia, lymphoma and autoimmune disorders or miRNAs that functionally target specific transcripts encoding cytokines, other immunological regulatory proteins and immune response signaling pathway components. We found that sHLA-G modulated the expression of miR-451 and miR-210 in activated CD4 + T cells. Our results may pave the way to further investigations on a possible sHLA-G-mediated modulation of miRNAs in physiological and pathological conditions.
Methods

HLA-G1/G5 production
Recombinant HLA-G1/G5 protein was produced in the human lymphoblastoid cell line 721.221.G1 (kindly provided by Dr Francesco Puppo, DIMI, Genova) by transfection of the 721.221 parental cell line with human HLA-G1 cDNA (25) .
Supernatants were collected from the 721.221.G1 cell line after 72-h culture in RPMI containing 10% fetal bovine serum (RPMI 10% FBS) at 37°C and 5% CO 2 , and subsequently purified using MEM-G/9 mAb and goat anti-mouse beads (Immunotech, Praha, Czech Republic). Soluble HLA-G was quantified by HLA-G1/G5-specific ELISA, as previously described (26) .
Cell cultures
The study was approved by the ethical committee of the G. Gaslini Institute, Genova, Italy. Peripheral blood samples were obtained from healthy donors following written informed consent. Mononuclear cells were isolated by Ficoll-Hypaque (Sigma) density gradient. CD4 + T cells were isolated from peripheral blood mononuclear cells samples using anti-CD4 microbeads (Myltenyi Biotec, Bergisch Gladbach, Germany) following the manufacturer's protocol. In some experiments, CD4 + T cells were stained with carboxyfluorescein diacetate succinimidyl ester (CFSE; Invitrogen, 1 µg/ml, 10 min at 37°C), washed and then stimulated as described below. CD4 + T cells were stimulated in vitro for 48 h in RPMI 10% FBS at 37°C and 5% CO 2 with anti-CD3 mAb (OKT3, coated overnight on 96-well plates), in the presence or absence of sHLA-G (100 ng/ml). Next, cells were washed and subjected to flow cytometric analysis or RNA extraction.
Flow cytometry
CD4
+ T cells were stained with FITC-conjugated anti-CXCR3 mAb (R&D systems) for 20 min at 4°C and then washed with PBS and 1% FBS (Sigma). The expression of CXCR3 and CD4 + T-cell proliferation (assessed by CFSE dilution) were investigated by running cells on a Gallios cytometer (Beckman Coulter). Data were analyzed using Kaluza software (Beckman Coulter).
RNA extraction, reverse transcription and quantitative real-time PCR
Total RNA or miRNA-enriched RNA preparations were extracted from CD4 + T cells using the miRNeasy Mini kit (Qiagen), following the manufacturer's procedures. RNA was quantified using a NanoDrop spectrophotometer (NanoDrop products, Wilmington, DE, USA). Total RNA (1 µg) was incubated for 5 min at 42°C with GE buffer (SABiosciences, Frederick, MD, USA) to eliminate genomic DNA contamination and then reverse transcribed using RT 2 First Strand Kit (SABiosciences), following the manufacturer's procedures.
miRNA expression was evaluated in miRNA-enriched RNA preparations using Human Immunopathology miRNA PCR Array (SABiosciences). SNORD44, SNORD47, SNORD48 and U6 were used as housekeeping genes.
The expression of miRNA downstream genes was evaluated on total RNA preparations using a customized RT 2 PCR Array (SABiosciences) that included the following genes: PSMB8 (proteasome subunit, beta type, 8), TBC1D9B (TBC1 domain family, member 9B), AIFM3 (apoptosis-inducing factor, mitochondrion-associated 3), SLC25A26 (solute carrier family 25, member 26), ATAD2B (ATPase, AAA domain-containing protein 2B), COL3A1 (collagen, type III, alpha 1), HBP1 (HMG-box transcription factor 1), HMCN1 (hemicentin 1), OSR1 (oddskipped related 1), VAMP7 (vesicle-associated membrane protein 7), CXCL16 (chemokine C-X-C motif ligand 16), GRSF1 (G-rich RNA sequence binding factor 1), MEX3C (RNA-binding protein) and C11orf30. GAPDH and C11orf30 (chromosome 11 open reading frame 30) were used as housekeeping genes.
Quantitative real-time PCR (qRT-PCR) analysis was performed following the manufacturer's protocols, using ABI 7700 (Applied Biosystems, Foster City, CA, USA) with the following cycling conditions: 95°C for 2 min, 40 cycles at 95°C for 15 s and at 60°C for 1 min.
Sequence Detection System software (Applied Biosystems) was used to determine threshold cycle (Ct) values. Average ΔCt values were calculated using PCR Array Data Analysis software v3. 
miRNA mimics and inhibitors
In some experiments, CD4 + T cells were transfected with (i) miR-210 mimic, (ii) miR-210 inhibitor, (iii) miR-451 mimic or (iv) miR-451 inhibitor (Qiagen) using HiPerFect Transfection Reagent (Qiagen), following the manufacturer's protocol. Cells were then washed and cultured for 24 h in RPMI 10% FBS at 37°C and 5% CO 2 before being used for further experiments.
Statistics
Statistical analysis was performed using Prism 5.03 software (GraphPad Software). Gaussian distribution of data was analyzed using the Kolmogorov-Smirnov test. The Student's t-test or Mann-Whitney test was used to compare data, depending on data distribution. The significance range was as follows: *P < 0.05 (significant), **P < 0.005, and ***P < 0.0005.
Results
sHLA-G down-regulated miR-451 and up-regulated miR-210 expression in activated CD4
+ T lymphocytes
The expression of 87 human miRNA, which have been previously characterized for their role in immunology and 280 sHLA-G modulates microRNAs in CD4+ T cells immunopathology, was evaluated by qRT-PCR on activated CD4 + T cells and cultured in the presence or absence of 100 ng/ml sHLA-G. This concentration was chosen on the basis of a previous study performed on CD4 + T cells (11) . Means of results obtained from six different experiments are summarized in Table. The high variability observed among six different experiments may be related to (i) a different activation status of CD4 + T cells in different donors or (ii) an interaction with different environmental factors, such as cytokines, growth factors and so on.
The expression of 11 out of 87 miRNAs was modulated by sHLA-G, with at least a 2.5-fold ratio between treated and untreated cells (these miRNAs are highlighted in Table 1) . However, as shown in Fig. 1, panel A, sHLA-G-mediated modulation was statistically significant only for two miRNAs. In particular, sHLA-G significantly (i) down-regulated the expression of miR-451 (2 −ΔCt value ± SD: untreated −1.24 ± 0.29 versus treated −1.6 ± 0.18; Student's t-test P = 0.02) and (ii) up-regulated the expression of miR-210 (2 −ΔCt value ± SD: untreated −1.49 ± 0.6 versus treated −1.05 ± 0.03, Student's t-test P = 0.05).
Modulation of miR-451 and miR-210 expression is not implicated in sHLA-G-mediated inhibition of proliferation and CXCR3 expression in activated CD4 + T cells
It has been previously demonstrated that sHLA-G (i) inhibits proliferation and (ii) down-modulates expression and function of different chemokine receptors on CD4 + T cells. We tested whether sHLA-G-mediated modulation of miR-451 and miR-210 expression was related to these effects. CXCR3 expression was evaluated because the expression of this receptor was strongly down-modulated by sHLA-G in mostly T-cell subsets (11) .
First, CD4 + T cells were transfected with miR-210 mimic or miR-451 inhibitor, to mimic sHLA-G-mediated modulation. However, as shown in Fig. 1, CD4 + T cells transfected with miR-210 mimic or miR-451 inhibitor did not show any inhibition of T-cell proliferation (panel B) or modulation of CXCR3 expression (panel C).
Next, CD4 + T cells were transfected with miR-210 inhibitor or miR-451 mimic to counterbalance the modulation induced by sHLA-G. Cells were then cultured in the presence or absence of sHLA-G. sHLA-G significantly inhibited proliferation (Fig. 1, panel B , % proliferating cells ± SD: ctr 84.4 ± 2.07 versus sHLA-G 60.8 ± 0.18, Mann-Whitney test P = 0.003) and CXCR3 expression (Fig. 1 , panel C, % CXCR3 + cells ± SD: ctr 57.5 ± 4.4 versus sHLA-G 41.1 ± 4.2, Mann-Whitney test P = 0.03) on CD4 + T cells, as previously described. However, neither miR-210 inhibitor nor miR-451 mimic were effective in counteracting the modulation of proliferation (panel A) and CXCR3 expression (panel B) performed by sHLA-G.
OSR1, CXCL16, C11orf30 and HBP-1 gene expression is modulated by sHLA-G in activated CD4
+ T cells We tested the expression of these genes by qRT-PCR in activated CD4
+ T cells cultured in the presence or absence of sHLA-G. As shown in Fig. 2 sHLA-G modulates microRNAs in CD4+ T cells 281 (Fig. 2) .
Discussion
To our knowledge, we have here provided the first evidence that sHLA-G may modulate the expression of miRNAs in immune effector cells.
In particular, we have reported a modulation of miR-210 and miR-451 expression performed by sHLA-G in activated CD4 + T cells. We have demonstrated that modulation of miR-210 and miR-451 was not functionally related to sHLA-G-mediated inhibition of proliferation or modulation of chemokine receptors expression in CD4 + T cells. We have analyzed sHLA-G-mediated modulation of different putative downstream genes of miR-451 and miR-210 that have been selected on the basis of different prediction 
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algorithms. We have found that sHLA-G up-regulated the expression of HBP-1 and OSR-1 and down-regulated the expression of CXCL16 and C11orf30 in CD4 + T cells. HBP-1 is a transcriptional repressor, whereas OSR-1 is a chloride cotransporter. No information is so far available of their function in CD4 + T cells. However, by up-regulating the expression of a transcriptional repressor, sHLA-G may affect the expression of several downstream genes.
CXCL16 is a chemokine that mediates the homing of CD8 + T cells into human skin, and thereby, it contributes to psoriasis pathogenesis. No information is available on CXCL16 expression and/or release in CD4 + T cells. In principle, sHLA-G-mediated down-modulation of CXCL16 release by CD4 + T cells may contribute to amelioration of psoriasis symptoms. Accordingly, sHLA-G has been previously detected in psoriatic skin and correlated with a better prognosis (27) .
The C11orf30 gene, whose expression was dampened by sHLA-G, is a putative target of miR-451 that is also downregulated by sHLA-G. We can speculate that C11orf30 is an indirect target gene that in turn may be regulated by other transcription factor(s) that are directly targeted by miR-451, as previously described for the COX-2 gene (28) . EMSY, which is encoded by the C11orf30 gene, is an oncogenic interacting partner of BRCA2 that functions also as a transcriptional repressor (29) . Again, sHLA-G may influence the expression of several downstream genes by modulating the expression of a transcriptional repressor.
In conclusion, sHLA-G-mediated modulation of miR-210 and -451 may have a role in the immunoregulatory properties of this molecule, possibly through the regulation of gene transcription.
Our data warrant further investigations aimed to (i) clarify the role of miRNAs in sHLA-G-mediated immunoregulation, and (ii) analyze a possible modulation of the expression of additional miRNAs performed by sHLA-G. Moreover, additional studies are needed to assess a possible sHLA-Gmediated modulation of miRNA expression in different cell populations.
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